title: Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
abstract: BACKGROUND
  Prostate-specific antigen (PSA) is the single most important tumor marker in early detection and monitoring of prostate cancer (CaP). However, routine analysis of serum PSA concentrations does not allow differentiation between CaP and prostatic diseases. The aim of the present study was to evaluate the usefulness of the serum-to-urinary PSA ratio in a clinical setting.
  
  
  METHODS
  In a retrospective clinical study, we determined serum and urine PSA concentrations in 48 patients with benign prostatic hyperplasia (BPH) and 57 patients with histologically confirmed CaP.
  
  
  RESULTS
  The serum-to-urinary PSA ratio is able to discriminate BPH from CaP.
  
  
  CONCLUSIONS
  Determination of the serum-to-urinary PSA ratio enhances the specificity of PSA in screening for CaP and monitoring of patients with CaP under androgen deprivation therapy.
authors.affiliation: Department of Urology, Faculty of Medicine, University of Rostock, Ernst-Heydemann-Str. 6, D-18057 Rostock, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Hillenbrand
authors.forename: M
authors.initials: M
authors.lastname: Bastian
authors.forename: M
authors.initials: M
authors.lastname: Steiner
authors.forename: C
authors.initials: C
authors.lastname: Zingler
authors.forename: M
authors.initials: M
authors.lastname: Müller
authors.forename: J M
authors.initials: JM
authors.lastname: Wolff
authors.forename: H
authors.initials: H
authors.lastname: Seiter
authors.forename: P
authors.initials: P
authors.lastname: Schuff-Werner
mesh_terms: D000368:Aged; D006801:Humans; D008297:Male; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood* / Q000652:urine; D011470:Prostatic Hyperplasia / Q000097:blood* / Q000175:diagnosis / Q000652:urine; D011471:Prostatic Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000652:urine
chemical_list: D017430:Prostate-Specific Antigen